These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 30117059)

  • 1. Pompe Disease: From Basic Science to Therapy.
    Kohler L; Puertollano R; Raben N
    Neurotherapeutics; 2018 Oct; 15(4):928-942. PubMed ID: 30117059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.
    Raben N; Schreiner C; Baum R; Takikita S; Xu S; Xie T; Myerowitz R; Komatsu M; Van der Meulen JH; Nagaraju K; Ralston E; Plotz PH
    Autophagy; 2010 Nov; 6(8):1078-89. PubMed ID: 20861693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine muscle cell models for Pompe disease and their use in studying therapeutic approaches.
    Takikita S; Myerowitz R; Zaal K; Raben N; Plotz PH
    Mol Genet Metab; 2009 Apr; 96(4):208-17. PubMed ID: 19167256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
    Meena NK; Raben N
    Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Autophagy in skeletal muscle: implications for Pompe disease.
    Shea L; Raben N
    Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The new era of Pompe disease: advances in the detection, understanding of the phenotypic spectrum, pathophysiology, and management.
    Kishnani PS; Beckemeyer AA; Mendelsohn NJ
    Am J Med Genet C Semin Med Genet; 2012 Feb; 160C(1):1-7. PubMed ID: 22253049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of Autophagy in Pompe Disease.
    Do H; Meena NK; Raben N
    Biomolecules; 2024 May; 14(5):. PubMed ID: 38785980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Autophagy and lysosomes in Pompe disease.
    Fukuda T; Roberts A; Ahearn M; Zaal K; Ralston E; Plotz PH; Raben N
    Autophagy; 2006; 2(4):318-20. PubMed ID: 16874053
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of autophagy in the pathogenesis of Pompe disease.
    Raben N; Roberts A; Plotz PH
    Acta Myol; 2007 Jul; 26(1):45-8. PubMed ID: 17915569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
    McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
    Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pompe Disease and Autophagy: Partners in Crime, or Cause and Consequence?
    Rodríguez-Arribas M; Pedro JM; Gómez-Sánchez R; Yakhine-Diop SM; Martínez-Chacón G; Uribe-Carretero E; De Castro DC; Casado-Naranjo I; López de Munaín A; Niso-Santano M; Fuentes JM; González-Polo RA
    Curr Med Chem; 2016; 23(21):2275-85. PubMed ID: 27237817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in diagnosis and management of Pompe disease.
    Davison JE
    J Mother Child; 2020 Oct; 24(2):3-8. PubMed ID: 33554498
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.
    Sun B; Zhang H; Bird A; Li S; Young SP; Koeberl DD
    J Gene Med; 2009 Oct; 11(10):913-20. PubMed ID: 19621331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic approaches in glycogen storage disease type II/Pompe Disease.
    Schoser B; Hill V; Raben N
    Neurotherapeutics; 2008 Oct; 5(4):569-78. PubMed ID: 19019308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of mTOR signaling as a strategy for the treatment of Pompe disease.
    Lim JA; Li L; Shirihai OS; Trudeau KM; Puertollano R; Raben N
    EMBO Mol Med; 2017 Mar; 9(3):353-370. PubMed ID: 28130275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What else is in store for autophagy? Exocytosis of autolysosomes as a mechanism of TFEB-mediated cellular clearance in Pompe disease.
    Feeney EJ; Spampanato C; Puertollano R; Ballabio A; Parenti G; Raben N
    Autophagy; 2013 Jul; 9(7):1117-8. PubMed ID: 23669057
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defect in degradation of glycogenin-exposed residual glycogen in lysosomes is the fundamental pathomechanism of Pompe disease.
    Zhang N; Liu F; Zhao Y; Sun X; Wen B; Lu JQ; Yan C; Li D
    J Pathol; 2024 May; 263(1):8-21. PubMed ID: 38332735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The efficacy of enzyme replacement therapy in pompe disease and secondary pathology in pompe muscle "excessive autophagy" which is relevant to the therapy resistance].
    Fukuda T
    No To Hattatsu; 2010 Mar; 42(2):114-6. PubMed ID: 23858594
    [No Abstract]   [Full Text] [Related]  

  • 19. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.
    Liang Q; Vlaar EC; Pijnenburg JM; Rijkers E; Demmers JAA; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
    J Proteomics; 2024 Jan; 291():105037. PubMed ID: 38288553
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined aerobic exercise and enzyme replacement therapy rejuvenates the mitochondrial-lysosomal axis and alleviates autophagic blockage in Pompe disease.
    Nilsson MI; MacNeil LG; Kitaoka Y; Suri R; Young SP; Kaczor JJ; Nates NJ; Ansari MU; Wong T; Ahktar M; Brandt L; Hettinga BP; Tarnopolsky MA
    Free Radic Biol Med; 2015 Oct; 87():98-112. PubMed ID: 26001726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.